ATOVAQUONE AND PROGUANIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Atovaquone And Proguanil Hydrochloride patents expire, and what generic alternatives are available?
Atovaquone And Proguanil Hydrochloride is a drug marketed by Glenmark Pharms Ltd and Mylan and is included in two NDAs.
The generic ingredient in ATOVAQUONE AND PROGUANIL HYDROCHLORIDE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone And Proguanil Hydrochloride
A generic version of ATOVAQUONE AND PROGUANIL HYDROCHLORIDE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What are the global sales for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
- What is Average Wholesale Price for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE?
Summary for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 25 |
Patent Applications: | 1 |
DailyMed Link: | ATOVAQUONE AND PROGUANIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The 108 Military Central Hospital | Phase 4 |
Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI) | Phase 4 |
Naval Medical Research Unit TWO (NAMRU-2) | Phase 4 |
See all ATOVAQUONE AND PROGUANIL HYDROCHLORIDE clinical trials
Pharmacology for ATOVAQUONE AND PROGUANIL HYDROCHLORIDE
Drug Class | Antimalarial Antiprotozoal |
Mechanism of Action | Dihydrofolate Reductase Inhibitors |